Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Genmab A/S (GNMSF : OTC)

• Company Description    Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark. Number of Employees: 2,682

• Price / Volume Information    Yesterday's Closing Price: $219.75 Daily Weekly Monthly 20 Day Moving Average: 38 shares Shares Outstanding: 66.07 (millions) Market Capitalization: $14,519.88 (millions) Beta: 0.91 52 Week High: $292.80 52 Week Low: $170.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.90% -1.32% 12 Week 7.57% -6.31% Year To Date 5.96% -1.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL CARL JACOBSENS VEJ 30 - VALBY,G7 2500 DNK ph: 45-7020-2728 fax: 45-7020-2729 ir@genmab.com http://www.genmab.com

• General Corporate Information    Officers Jan G. van de Winkel - President and Chief Executive Officer Anthony Mancini - Executive Vice President and Chief Operating Offic Anthony Pagano - Executive Vice President and Chief Financial Offic Judith Klimovsky - Executive Vice President Birgitte Stephensen - Executive Vice President Peer Information Genmab A/S (CORR.) Genmab A/S (RSPI) Genmab A/S (CGXP) Genmab A/S (BGEN) Genmab A/S (GTBP) Genmab A/S (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: K3967W102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 66.07 Most Recent Split Date: (:1) Beta: 0.91 Market Capitalization: $14,519.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 14.85 PEG Ratio: - Price Ratios Price/Book: 2.74 Price/Cash Flow: 14.47 Price / Sales: 4.49 EPS Growth vs. Year Ago Period: 3.74% vs. Previous Quarter: -46.49% Sales Growth vs. Year Ago Period: 18.53% vs. Previous Quarter: -22.39% ROE 06/30/25 - - 03/31/25 - 19.23 12/31/24 - 19.75 ROA 06/30/25 - - 03/31/25 - 15.44 12/31/24 - 16.23 Current Ratio 06/30/25 - - 03/31/25 - 5.34 12/31/24 - 5.25 Quick Ratio 06/30/25 - - 03/31/25 - 5.32 12/31/24 - 5.24 Operating Margin 06/30/25 - - 03/31/25 - 29.44 12/31/24 - 30.43 Net Margin 06/30/25 - - 03/31/25 - 35.11 12/31/24 - 36.30 Pre-Tax Margin 06/30/25 - - 03/31/25 - 40.96 12/31/24 - 42.57 Book Value 06/30/25 - - 03/31/25 - 80.15 12/31/24 - 80.53 Inventory Turnover 06/30/25 - - 03/31/25 - 17.23 12/31/24 - 14.25 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©